21:20 , Nov 9, 2017 |  BC Innovations  |  Finance

The return of big

After a slow second quarter, pharmas have stepped up their activity in public-private partnerships, announcing 13 in 3Q17, compared with only five in the quarter before. The deals bring the third quarter total to 56,...
03:17 , Jun 9, 2017 |  BC Week In Review  |  Financial News

Oncobiologics raises $1.5M to complete $10M private placement

On May 31, biosimilar company Oncobiologics Inc. (NASDAQ:ONS) raised $1.5 million through the sale of 5% senior secured promissory notes in the final portion of a planned $10 million private placement. Investors also received warrants...
02:10 , Feb 14, 2017 |  BioCentury  |  Regulation

From similar to same

FDA’s draft guidance on demonstrating interchangeability with a reference product cracks open a door into a generics-like marketplace but, in many settings, manufacturers may decide it isn’t worth the expense. The guidance sets a high...
20:38 , Jan 6, 2017 |  BC Week In Review  |  Financial News

Oncobiologics completes private placement of senior notes and warrants

Oncobiologics raised $8.4 million through the sale of 5% senior secured promissory notes in an initial close of a planned $10 million private placement with accredited investors. The notes mature on Dec. 22. Investors also...
07:00 , Jul 25, 2016 |  BioCentury  |  Strategy

Paving the way

Amgen Inc. and the Sandoz unit of Novartis AG are charting a course that could create competitive U.S. markets for two of the biggest prizes in the biosimilars universe, AbbVie Inc.'s Humira adalimumab and Amgen's...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 11a (RANK; TNFRSF11A; CD265); receptor activator of NF-κB ligand (RANKL; TNFSF11); breast cancer

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting RANKL could help treat BRCA1-mutant breast cancer. In tissue samples from breast cancer patients, levels of the RANKL receptor RANK were higher in tumors and adjacent...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers and...
07:00 , May 23, 2016 |  BioCentury  |  Finance

Summer sweeteners

Biotechs looking to tap the markets are sweetening their deal terms with deep discounts or bells and whistles such as warrants. The goal is to entice the handful of buysiders shopping for bargains because they...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Oncobiologics Inc. completes private placement of units

Oncobiologics Inc. (NASDAQ:ONS), Cranbury, N.J.   Business: Antibodies, Autoimmune, Cancer   Date completed: 2016-05-12   Type: Private placement of units   Raised: $5 million   Units: 833,332   Price: $6 (unit)   Shares after offering: 22.8 million   Investor: Sabby Management LLC   Note:...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Oncobiologics Inc. completes IPO

Oncobiologics Inc. (NASDAQ:ONS), Cranbury, N.J.   Business: Antibodies, Autoimmune, Cancer   Date completed: 2016-05-12   Type: IPO   Raised: $35 million   Shares: 5.8 million   Price: $6 (unit)   Shares after offering: 22.8 million   Underwriters: Jefferies; Barclays Capital; Cantor Fitzgerald   Overallotment:...